ENvue Medical's $50 million equity facility shows how differently micro-caps are paying for capital

by Jonas Halvorsen · August 12, 2026

Companies Reporter, The MicroCap Herald

ENvue Medical said on Wednesday, Aug. 12, that it had entered a securities purchase agreement establishing a committed equity facility of up to $50 million, announced through GlobeNewswire and disclosed the same day in an 8-K. The release described the intended use broadly — advancing the company's next-generation technology platform and evaluating selective acquisition and business development opportunities — and Chief Executive Doron Besser said in the release: "With greater financial flexibility, we believe we will be able to evaluate opportunities to acquire technologies, products or businesses that can accelerate our strategy." The release carried no pricing mechanics. The filing did.

According to StockTitan's summary of the 8-K, the facility lets ENvue sell shares to the investor at a purchase price equal to 90% of the lowest volume weighted average price of the common shares during the three trading days preceding a draw. The term runs 36 months from commencement, which occurs when the related SEC registration becomes effective, and the company may exit without penalty on five trading days' notice after that point. The company's press release states the facility is subject to the receipt of stockholder approval. Notably, the summary describes a discount mechanism rather than a minimum price threshold, and discloses no floor price.

That distinction is the whole of the dilution question. In a facility priced at a fixed discount to a trailing low VWAP with no floor, the dollar amount is capped at $50 million but the share count required to raise it is not capped at all. If the stock falls, each draw issues more shares, typically sold into the same thin market that set the reference price. The headline $50 million describes a ceiling on proceeds, not on issuance.

The 8-K also specifies where the money goes first: 40% of net proceeds from any sales are directed to redeeming Series X Preferred Stock, the remainder to working capital and general corporate purposes. A meaningful share of capital raised through common-stock dilution is therefore earmarked to retire a senior instrument rather than fund operations. The same day, ENvue disclosed an amendment expanding the additional investment rights attached to its Series H preferred to $59,000,000 in stated value — 59,000 preferred shares and $53,100,000 of subscription amount — with no less than $10.0 million to be exercised in the twelve months following shareholder approval, at a monthly minimum of $833,333.33. That minimum steps down dollar for dollar upon specified fundraising events.

A very different structure was on the tape days earlier. Femasys announced on Aug. 7 a $30 million private placement, selling 9,374,999 common shares at $3.20 apiece alongside pre-funded warrants priced at $3.1999, with 18,749,998 accompanying warrants exercisable at $2.95, per its GlobeNewswire release. Full cash exercise would bring in up to $60 million more, contingent on investor discretion and, for the milestone tranche, milestone achievement. Nantahala Capital led, with Rosalind Advisors and members of management participating; Laidlaw & Company (UK) Ltd. was placement agent. Closing was expected on or around Aug. 10.

The trade-off between those designs is straightforward. Femasys fixed its price and knows exactly how many shares it sold; what it does not control is whether the 18.75 million warrants are ever exercised, and that overhang sits above the stock at $2.95 regardless. ENvue fixed its ceiling on proceeds and left the share count floating with the market. The two simply put the uncertainty in different places, and both meaningfully expand the share base of a company whose float is small to begin with.

A third variant, from earlier in the summer, shows what the terms look like when a company borrows instead. OS Therapies disclosed in an 8-K filed July 2, 2026 a secured convertible note facility of up to $10 million with Leonite Fund I, LP, entered into June 30, with a first tranche of $1,600,000 funded July 2 at a 7.5% original issue discount and $35,000 retained by the investor for legal fees, per StockTitan's summary of the filing. The notes carry 9.0% annual interest payable monthly, a $2.05 conversion price, and tranche maturities of nine months up to 24 months from issuance. The lender also received warrants for 1,750,000 shares at $2.85 running through June 30, 2031, plus 275,000 commitment shares. Ownership is blocked at 4.99%, increasable to 9.99% on notice, and conversions are capped at 19.99% of shares outstanding absent stockholder approval.

The protective terms on that instrument are worth reading before drawing conclusions about cost of capital. The summary describes anti-dilution reset provisions taking effect Sept. 30, 2026, a 110% prepayment penalty, and a default regime under which obligations accelerate to 125% of principal, interest rises to 24% annually and a $10,000 monthly monitoring fee applies. The notes are secured by a first-priority lien on substantially all assets, excluding intellectual property itself though including related payment rights — a claim that ranks ahead of common equity. Management has said the financing supports clinical development, regulatory activities and working capital, with runway projected into 2027 supported by approximately $10.2 million in expected U.K. tax credit refunds by the end of 2026, a projection that depends on those refunds arriving on schedule.

Across all three, the risks are the ones that recur at this end of the market: reset provisions that increase issuance when prices fall, exchange caps and ownership blockers that stagger rather than eliminate conversion, stockholder-approval conditions that can delay or block a facility entirely, secured claims senior to common stock, and secondary markets thin enough that conversion selling moves the price it is measured against. The Russell 2000's 0.61% gain on Wednesday changed none of those mechanics.